A compound for treating pulmonary hypertension and its application
A technique for pulmonary hypertension and compounds, applied in medical preparations containing active ingredients, organic chemistry, drug combinations, etc., can solve the problems that cannot be treated with pulmonary hypertension
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0018] Embodiment 1: Preparation of CS303
[0019] (1) Synthesis of compound Ⅰ
[0020]
[0021] Add ethyl 1,4-diazacyclo-1-carboxylate (159g, 0.924mol) into a three-necked flask, then add pyridine (2.5L), add ethylsulfonyl chloride (141.9, 1.1mol) dropwise at room temperature, After the dropwise addition was completed, continue to stir at room temperature for 2 hours, monitor the disappearance of the raw material spots by TLC spotting (iodine color development), add dilute hydrochloric acid and ethyl acetate, extract, leave to stand and separate the layers, separate the organic layer, add anhydrous sodium sulfate to dry, After filtration, the filtrate was concentrated under reduced pressure to obtain 268.4 g of compound I as a white solid, with a yield of 91%. 1 HNMR (400MHz, DMSO-d6): δppm4.12(t, 2H), 3.61(t, 2H), 3.09(m, 2H), 2.98-2.86(m, 4H), 2.64(m, 2H), 1.68( m, 2H), 1.29(m, 3H), 1.27(m, 3H); ESI / MS: m / z=265(M+H) + .
[0022] (2) Synthesis of compound CS303 (formu...
Embodiment 2
[0025] Example 2: Effect test of CS303 on pulmonary hypertension caused by hypoxia
[0026] SD rats, male, weighing 200±20g, were randomly divided into five groups, namely normal control group, model control group, CS303 low-dose group (13mg / kg / d), CS303 medium-dose group (26mg / kg / d), CS303 high-dose group (52mg / kg / d), 10 rats in each group. The rats in the normal control group were raised in a normal pressure environment, and the rats in the other groups were raised in a fully automatic adjustment low-pressure hypoxic chamber (atmospheric pressure about 50kPa, oxygen concentration 10%), and intermittent hypoxia was carried out for 8 hours a day for a continuous 6 weeks. In the CS303 treatment group, 2 weeks after the start of modeling, intragastric administration was administered once before each hypoxia, and lasted for 4 weeks. Two weeks after the start of modeling, the normal control group and the model control group were intragastrically administered a considerable amoun...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


